Second generation Optune system is less than half the weight and size of first generation Optune system New system aims to make Optune therapy even easier for glioblastoma (GBM) patients Novocure's ...

Preclinical studies demonstrate that Tumor Treating Fields increase sensitivity to radiation therapy and inhibit DNA damage repair ST. HELIER, Jersey--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) today ...

ST. HELIER, Jersey--(BUSINESS WIRE)-- Novocure (NASDAQ:NVCR) announced today that the Swiss Federal Office of Public Health (BAG) has added Optune in combination with temozolomide to the List of ...

NovoCure recently secured approval for its Optune Lua® device in Japan, a milestone for the company’s TTFields therapy that targets non-small cell lung cancer. This development aligns with the company ...

Optune Lua is now approved for use concurrently with immune checkpoint inhibitors or docetaxel in adult patients with metastatic NSCLC who have progressed on or after a platinum-based regimen CE Mark ...

Take a close watchful eye on little known biomedical Novocure (NVCR), whose novel anti-cancer therapy is catching Wall Street’s attention. Its stock has rallied robustly from a low of $15 a share on ...

For the first time in more than a decade, there's a new treatment for patients diagnosed with one of the most common and deadly forms of brain cancer, known as glioblastoma or GBM. More than 12,000 ...

Novocure has provided stellar returns over the last five years, now up 17 times. Recent positive news may keep its stock going up. Currently, Optune is approved for glioblastoma multiforme. The ...

ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) today announced the first patient has been enrolled in its global phase 3 TRIDENT trial, a randomized study in newly diagnosed glioblastoma ...

For the first time in more than a decade, there’s a new treatment for patients diagnosed with one of the most common and deadly forms of brain cancer, known as glioblastoma or GBM. More than 12,000 ...

TRIDENT will test the potential survival benefit of initiating Optune concurrent with radiation therapy in patients with newly diagnosed glioblastoma Preclinical studies demonstrate that Tumor ...